Literature DB >> 17206636

The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients.

Lene Riis1, Ida Vind, Severine Vermeire, Frank Wolters, Kostas Katsanos, Patrizia Politi, João Freitas, Ioannis A Mouzas, Colm O'Morain, Victor Ruiz-Ochoa, Selwyn Odes, Vibeke Binder, Pia Munkholm, Bjørn Moum, Reinhold Stockbrügger, Ebbe Langholz.   

Abstract

BACKGROUND AND AIM: The aetiology of inflammatory bowel disease (IBD) is unknown, but it has become evident that genetic factors are involved in disease susceptibility. Studies have suggested a north-south gradient in the incidence of IBD, raising the question whether this difference is caused by genetic heterogeneity. We aimed to investigate the prevalence of polymorphisms in CARD15 and TLR4 and occurrence of anti-Saccharomyces cerevisiae (ASCA) and antineutrophil cytoplasmic antibodies (pANCA) in a European population-based IBD cohort.
METHODS: Individuals from the incident cohort were genotyped for three mutations in CARD15 and the Asp299gly mutation in TLR4. Levels of ASCA and pANCA were assessed. Disease location and behaviour at time of diagnosis was obtained from patient files.
RESULTS: Overall CARD15 mutation rate was 23.9% for CD and 9.6% for UC patients (P < 0.001). Mutations were less present in the Scandinavian countries (12.1%) versus the rest of Europe (32.8%) (P < 0.001). Overall population attributable risk was 11.2%. TLR4 mutation rate was 7.6% in CD, 6.7% in UC patients and 12.3% in healthy controls (HC), highest among South European CD patients and HC. ASCA was seen in 28.5% of CD patients with no north-south difference, and was associated with complicated disease. pANCA was most common in North European UC patients and not associated with disease phenotype.
CONCLUSION: The prevalence of mutations in CARD15 varied across Europe, and was not correlated to the incidence of CD. There was no association between mutations in TLR4 and IBD. The prevalence of ASCA was relatively low; however related to severe CD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206636     DOI: 10.1002/ibd.20047

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  21 in total

1.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

2.  Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?

Authors:  James Markowitz; Subra Kugathasan; Marla Dubinsky; Ling Mei; Wallace Crandall; Neal LeLeiko; Maria Oliva-Hemker; Joel Rosh; Jonathan Evans; David Mack; Anthony Otley; Marian Pfefferkorn; Ron Bahar; Eric Vasiliauskas; Ghassan Wahbeh; Gary Silber; J Antonio Quiros; Iwona Wrobel; Justin Nebel; Carol Landers; Yoanna Picornell; Stephan Targan; Trudy Lerer; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 3.  Do we really understand what the immunological disturbances in inflammatory bowel disease mean?

Authors:  Epameinondas V Tsianos; Konstantinos Katsanos
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

Review 4.  New pathophysiological insights and modern treatment of IBD.

Authors:  Matthias A Engel; Markus F Neurath
Journal:  J Gastroenterol       Date:  2010-03-09       Impact factor: 7.527

5.  Common NOD2/CARD15 and TLR4 Polymorphisms Are Associated with Crohn's Disease Phenotypes in Southeastern Brazilians.

Authors:  Yolanda F M Tolentino; Paula Peruzzi Elia; Homero Soares Fogaça; Antonio José V Carneiro; Cyrla Zaltman; Rodrigo Moura-Neto; Ronir Raggio Luiz; Maria da Gloria C Carvalho; Heitor S de Souza
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

6.  Serologic Markers in the Diagnosis and Management of IBD.

Authors:  Severine Vermeire
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

7.  Analysis of TLR4 and TLR2 polymorphisms in inflammatory bowel disease in a Guangxi Zhuang population.

Authors:  Lan Chen; Mei-Jiao Lin; Ling-Ling Zhan; Xiao-Ping Lv
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 8.  Intestinal barrier in inflammatory bowel disease.

Authors:  Lena Antoni; Sabine Nuding; Jan Wehkamp; Eduard F Stange
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

9.  Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease.

Authors:  Luciana Rigoli; Claudio Romano; Rosario Alberto Caruso; Maria A Lo Presti; Chiara Di Bella; Vincenzo Procopio; Giuseppina Lo Giudice; Maria Amorini; Giuseppe Costantino; Maria D Sergi; Caterina Cuppari; Giovanna Elisa Calabro; Romina Gallizzi; Carmelo Damiano Salpietro; Walter Fries
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

10.  Evidence for impaired CARD15 signalling in Crohn's disease without disease linked variants.

Authors:  Jakob Benedict Seidelin; Oliver Jay Broom; Jørgen Olsen; Ole Haagen Nielsen
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.